Free Trial

Antares Pharma (ATRS) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
50-Day Range
52-Week Range
6 shs
Average Volume
3.29 million shs
Market Capitalization
$955.06 million
P/E Ratio
Dividend Yield
Price Target
ATRS stock logo

About Antares Pharma Stock (NASDAQ:ATRS)

Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey.

ATRS Stock News Headlines

Antares Vision SpA AV
Antares Vision Share Price (AV.MI)
270x more lucrative than NVIDIA???
If you've missed out on NVIDIA's recent 1,600% run... Don't worry. Because there's one AI stock that could be a lot more lucrative.
Antares Reaches New 52-Week High (AIS)
Antares Vision SpA (ANV)
COP Syringes Market Competitive Situation By 2030
270x more lucrative than NVIDIA???
If you've missed out on NVIDIA's recent 1,600% run... Don't worry. Because there's one AI stock that could be a lot more lucrative.
See More Headlines
Receive ATRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Antares Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Fiscal Year End

Industry, Sector and Symbol

Surgical & Medical Instruments
Health Care Supplies
Current Symbol
Year Founded


Net Income
$46.29 million
Pretax Margin


Sales & Book Value

Annual Sales
$183.98 million
Cash Flow
$0.13 per share
Book Value
$1.03 per share


Free Float
Market Cap
$955.06 million
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. Robert F. Apple (Age 56)
    CEO, Pres & Director
    Comp: $1M
  • Mr. Fred M. Powell CPA (Age 61)
    Exec. VP & CFO
    Comp: $636.39k
  • Mr. Peter J. Graham Esq. (Age 55)
    Exec. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec.
    Comp: $634.48k
  • Mr. Patrick Madsen
    Sr. VP of Operations
  • Mr. Keith Muckenhirn (Age 59)
    Principal Accounting Officer, VP of Fin. & Corp. Controller
  • Ms. Tram Bui
    VP of Corp. Communications & Investor Relations
  • Mr. Edward Tykot
    Sr. VP of Corp. Bus. Devel.
  • Mr. Claude E. Richardson
    Sr. VP of HR
  • Dr. Peter Sadowski (Age 74)
    Sr. VP of Technology Portfolio & Intellectual Property
  • Dr. Jonathan S. Jaffe
    Interim EVP, Pharmaceutical R&D and Chief Medical Officer

ATRS Stock Analysis - Frequently Asked Questions

How were Antares Pharma's earnings last quarter?

Antares Pharma, Inc. (NASDAQ:ATRS) released its earnings results on Thursday, November, 4th. The specialty pharmaceutical company reported $0.03 earnings per share for the quarter, meeting the consensus estimate of $0.03. The specialty pharmaceutical company earned $48.19 million during the quarter, compared to analyst estimates of $48.52 million. Antares Pharma had a net margin of 21.90% and a trailing twelve-month return on equity of 7.43%.

What is Paul K. Wotton's approval rating as Antares Pharma's CEO?

5 employees have rated Antares Pharma Chief Executive Officer Paul K. Wotton on Paul K. Wotton has an approval rating of 18% among the company's employees. This puts Paul K. Wotton in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Antares Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Antares Pharma investors own include Ballard Power Systems (BLDP), Advanced Micro Devices (AMD), Novavax (NVAX), NVIDIA (NVDA), Conatus Pharmaceuticals (CNAT) and Micron Technology (MU).

This page (NASDAQ:ATRS) was last updated on 7/19/2024 by Staff

From Our Partners